Answers are grounded in this paper and cite their sources.
A decade after preexposure prophylaxis against HIV became available, less than a quarter of people in the United States who could benefit from PrEP are taking it. The failure is, in part, a perverse outcome of a system that relies on high drug prices to fund HIV prevention.
No takes yet. Share an insight, caveat, or question.
Marcus et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: